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Simplified scoring of the Actionable 8-item
screening questionnaire for neurogenic
bladder overactivity in multiple sclerosis: a
comparative analysis of test performance at
different cut-off points
Peter Joseph Jongen1,2*, Bertil F. Blok3, John P. Heesakkers4, Marco Heerings5,6, Wim A. Lemmens7
and Rogier Donders7
Abstract
Background: The Actionable questionnaire is an 8-item tool to screen patients with multiple sclerosis (MS) for
neurogenic bladder problems, identifying those patients who might benefit from urological referral and bladder-specific
treatment. The original scoring yields a total score of 0 to 24 with cut-off point 6. A simplified scoring, yielding a total
score of 0 to 8 with cut-off point 3, has been developed in urogynaecological patients, but has not been investigated
in MS.
Methods: One-hundred-and-forty-one MS patients completed the Actionable on two occasions. We compared the test
performance of the simplified scoring with cut-off point 3 with that of cut-off point 2, using the original scoring with
cut-off point 6 as a gold standard. The following measures were calculated: True Positives (TP), True Negatives (TN),
False Positives (FP), False Negatives (FN), Sensitivity, Specificity, Positive Predictive Value (PPV), Negative Predictive Value
(NPV), and Accuracy. The associations between positive test result and urological treatment, and bladder-specific drug
treatment were calculated.
Results: For cut-off point 3 the outcomes (Test 1, Test 2) were: TP 43.26 %, 40.88 %; TN 29.79 %, 32.85 %; FP 0.00 %,
0.00 %; FN 26.95 %, 26.28 %; Sensitivity 0.62, 0.61; Specificity 1.00, 1.00; PPV 1.00, 1.00; NPV 0.53, 0.55; Accuracy 0.73,
0.74; and for cut-off point 2: TP 59.57 %, 59.85 %; TN 26.95 %, 31.39 %; FP 2.84 %, 1.46 %; FN 10.63 %, 7.30 %; Sensitivity
0.85, 0.89; Specificity 0.90, 0.96; PPV 0.95, 0.98; NPV 0.72, 0.81; Accuracy 0.87, 0.91. Cut-off 3 completely prevented FP
outcomes, but wrongly classified 26 % of the patients as negative (FN). Cut-off 2 reduced the FN to 7–10 %, with low
FP values (2.84–1.46 %). With cut-off 2, the percentage of patients screened positive was higher in the Progressive
group (75.00 %) than in the Relapsing Remitting group (56.25 %) (P = 0.0331), which was not the case with cut-off 3.
Only a positive test according to the original scoring was associated with both urological treatment (P = 0.0119)
and bladder-specific medication (P = 0.0328).
Conclusions: Our findings suggest that in MS patients the simplified Actionable scoring is more accurate with
cut-off point 2 than with cut-off point 3, especially by substantially reducing FN outcomes; and that in MS the
original Actionable scoring seems preferable.
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Background
The Actionable questionnaire is a short, 8-item, psycho-
metrically validated instrument that was developed in
response to the growing need to screen patients with
multiple sclerosis (MS) for neurogenic bladder problems
[1]. The questionnaire accurately identifies MS patients
with bladder symptoms who might benefit from uro-
logical referral and specific treatment [1]. It does so by
asking questions that uncover whether patients are ex-
periencing urinary symptoms, to what degree, and what
the effects of these symptoms are on daily life [1]. The
Actionable is a shortened version of the 16-item Action-
able Bladder Symptom Screening Tool (ABSST), that
was developed with the same purpose [2]. Both the
Actionable and the ABSST have been demonstrated to
have a high sensitivity and a high specificity of approxi-
mately 85 to 90 % [1, 2].
As reported by Bates et al. [1] the item scoring of the
Actionable is similar to that of the ABSST: each item is
scored on a 4-point scale that is indicated by boxes, ran-
ging from no symptoms or impact (most left hand box)
to extreme symptoms or impact (most right hand box).
From left to right the boxes are scored as 0, 1, 2 and 3.
The Actionable score is calculated as the sum of the
eight item scores and ranges from 0 (minimum) to 24
(maximum). The cut-off point for positivity is 6 [1].
In a recent study Cardozo et al. validated the Actionable
questionnaire also as a screening tool in women with in-
continence due to an overactive bladder, demonstrating a
sensitivity of 79 % and a specificity of 98 % [3]. However,
in that study the item scoring was different from that de-
scribed by Bates et al. [1]: any checked 3rd or 4th right
hand box incurred a point, and consequently the Action-
able score ranged from 0 (no checked 3rd or 4th right hand
box) to 8 (8 checked 3rd or 4th hand boxes). It is conceiv-
able that this simplified scoring system appeals to health
care professionals using the Actionable questionnaire as a
routine standard of care in their daily practice, as well as
to patients who use the questionnaire for self-screening in
the context of self-management. Interestingly, in the sim-
plified scoring the cut-off point indicating a need for uro-
logical evaluation of bladder function was 3 [3], whereas
intuitively a cut-off point of 6 in a scale from 0 to 24
would be expected to result in a cut-off point of 2 in a
scale from 0 to 8.
In view of the established validity of the simplified
Actionable scoring in women with overactive bladder
symptoms, we asked ourselves whether the scoring
would also be appropriate for use in patients with MS
and what would be the best cut-off point. So, we com-
pared the test performance of the cut-off points 3 and 2
in the simplified scoring (0 to 8), using the original
scoring (0 to 24) with cut-off point 6 as a gold standard
[1]. Here we report the results.
Methods
Study design and setting
The study was part of the Dutch Actionable validation
study, an observational non-interventional web-based
study in The Netherlands in the period January 2015 to
May 2015. The Dutch Actionable validation study assessed
the test-retest reliability and concurrent validity of a Dutch
version of the English Actionable questionnaire. The study
was investigator-initiated and investigator-sponsored with
financial support from Allergan Pharmaceutical Ireland
Inc. The inclusion criteria for participation were 1) having
been diagnosed with MS, 2) no relapse in the last 30 days,
and 3) willing and able to comply with the requirements
of the protocol, i.e. online completion of questionnaires
and having the Expanded Disability Status Scale (EDSS)
score assessed by phone. Patients were informed by the
urological departments of the Erasmus Medical Centre
and the Radboud University Nijmegen Medical Centre,
neurologists and MS nurses, the websites of patient orga-
nizations and of the MS4 Research Institute. The study
information and the consent form were available as down-
load on the website of the MS4 Research Institute
www.ms4ri.nl. After having given their written consent
patients received a personal code and logged on to the
website, to choose a username and password. The study
was performed using the LimeSurvey software, an open
source online application. To protect the personal data
from unauthorized access various mechanisms were used,
among others the use of a personal username and a strong
password, separation in the database of personal informa-
tion from the answers to the questions, each screen having
a username and password protection, Virtual Private Net-
work (VPN) tunnelling, 256-bits encryption, and the en-
cryption of the participants’ identities via unique 15 digits
codes. Automated completeness checks were done before
questionnaires could be submitted. The help desk (MH)
contacted respondents by phone in case they did not suc-
ceed in completing questionnaires. The study protocol was
presented to the ethical committee Medisch Ethische
Toetsingscommissie Brabant (nr NW2015-08) and the
committee concluded that a review was not indicated, as
the study did not qualify for being tested according to the
Dutch Medical Research Involving Human Subjects Act of
1999 (http://wetten.overheid.nl/BWBR0009408) [4]. The
study was performed in agreement with the Declaration of
Helsinki.
Disability was assessed by use of the EDSS score via
telephone. The EDSS is a generally accepted and widely
used measure of MS-related disability. The classical
EDSS is based on a neurological examination that pro-
vides the basis for the assessment of several functional
systems (visual, brainstem, pyramidal, cerebellar, sensory,
bowel and bladder, cerebral) that, according to prede-
fined algorithms, contribute to the EDSS score. An EDSS
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version for use by telephone via a structured interview
has been developed and validated [5].
Actionable questionnaire
The Actionable questionnaire was completed at base-
line (Day 1) and after 1 week (Day 8), primarily for as-
sessment of the test-retest reliability of the Dutch
version. For each of the assessments the Actionable
score was calculated in two ways. Firstly, according to
the original description by Bates et al., each item was
scored on a 4-point scale indicated by boxes, ranging
from no symptoms or impact (most left hand box) to
extreme symptoms or impact (most right hand box)
[1]. From left to right the boxes were scored as 0, 1, 2
and 3. The Actionable score was calculated as the sum
of the eight item scores and ranged from 0 (minimum)
to 24 (maximum). Secondly, according to the descrip-
tion by Cardozo et al., after having scored the items on
a 4-point scale as mentioned above, any checked 3rd or
4th right hand box incurred a point [3] (Fig. 1). Thus,
the simplified Actionable score ranged from 0 (no
checked 3rd or 4th right hand box) to 8 (eight checked
3rd or 4th hand boxes).
Statistics
To assess in MS patients the performance of the cut-off
points 3 and 2 in the simplified Actionable scoring (0 to 8),
the following measures were calculated, using the original
scoring (0 to 24) with cut-off point 6 as a gold standard:
the number of True Positives (TP), the number of True
Negatives (TN), the number of False Positives (FP), the
number of False Negatives (FN), Sensitivity TP/(TP + FN),
Specificity TN/(TN+ FP), Positive Predictive Value (PPV)
TP/(TP + FP), Negative Predictive Value (NPV) TN/(TN+
FN), and Accuracy (TP + TN)/(Positives +Negatives) [6].
Differences between groups for dichotomous variables
were tested using the Chi-square test. P values lower than
0.05 were considered statistically significant.
Fig. 1 Actionable 8-item screening questionnaire for neurogenic bladder overactivity in multiple sclerosis
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Results
One-hundred-and-forty-one patients were included in the
study, 106 females and 35 males. The mean (standard devi-
ation [SD]) age was 47.7 (10.40) years (minimum 24 years,
maximum 73 years), the mean (SD) disease duration 10.1
(8.0) years (minimum 0 years, maximum 35 years), and the
mean (SD) EDSS score 4.3 (1.8) (minimum 0.00, maximum
7.5). Eighty patients were relapsing remitting, 48 progres-
sive and in 13 patients the disease course was unknown.
Forty-five (31.91 %) patients were on bladder medication,
whereas 96 (68.09 %) were not. Fifty-six (39.72 %) patients
were seen by an urologist for overactive bladder symptoms,
whereas 85 (60.28 %) were not. The Day 8 assessment was
completed by 137 patients.
The mean, SD, minimum and maximum values of the
Actionable scores at Day 1 (Test 1) and at Day 8 (Test 2)
according to the original scoring system (0 to 24) and to
the simplified scoring system (0 to 8) are presented in
Table 1. The ratio between the mean score in the simplified
scoring (0 to 8) and the mean score in the original scoring
(0 to 24) was 0.3050 at Test 1 and 0.2972 at Test 2. Table 2
shows the numbers of patients tested positive and tested
negative with the use of cut-off point 3 and with the use of
cut-off point 2, as compared to the test results of the ori-
ginal scoring (cut-off point 6) at Test 1. Table 3 shows this
information for Test 2. Table 4 presents the statistical mea-
sures for the cut-off points 3 and 2 in the simplified scor-
ing, using the original scoring with cut-off 6 as a gold
standard. At both tests the use of cut-off point 3 resulted
in the complete absence of false positive patients, but also
in a false negative result in 38 patients (26.95 % of the total
population) at Test 1 and in 36 patients (26.27 % of the
total population) at Test 2. Accordingly, the sensitivity and
specificity at cut-off point 3 were 0.62, 0.61 and 1.00, 1.00
(Test1, Test 2). In contrast, at cut-off point 2 the numbers
of false positive and false negative patients were 4 (2.84 %)
and 15 (10.64 %) at Test 1, and 2 (1.46 %) and 10 (7.30 %)
at Test 2, the sensitivity was 0.95, 0.89 and the specificity
0.90, 0.96 (Test 1, Test 2). The differences in these per-
formance measures between the cut-off points 3 and 2
were reflected by the accuracy, being 0.73, 0.74 at cut-off 3
and 0.87, 0.91 at cut-off 2 (Test 1, Test 2).
For each of the three modes of screening (original
with cut-off 6, simplified with cut-off 3, simplified with
cut-off 2) the percentages of positive and negative pa-
tients that were treated by an urologist for MS-related
bladder problems, and the percentages of patients that
were taking medication for MS-related bladder prob-
lems are presented in Table 5. Differences between the
percentages of positive and negative patients in both
categories only occurred in the original scoring system.
When comparing the RRMS group with the progressive
group, it was found that with the original scoring (0 to 24,
cut-off 6) and with the simplified scoring and cut-off 2,
the percentage of patients that was screened positive was
higher in the progressive group (85.42 and 75.00 %, re-
spectively) than in the RRMS group (65.00 and 56.25 %,
respectively) (P = 0.0121 and P = 0.0331, respectively). This
was not the case with the use of the simplified scoring and
cut-off 3 (54.17 % vs. 38.75 %; P = 0.0893).
Discussion
In contrast to the original scoring of the Actionable ques-
tionnaire [1], the simplified scoring (0 to 8) had, to our
knowledge, not previously been investigated in MS patients
[1–3]. We assessed the test performance of the cut-off
points 3 and 2 in the simplified scoring, using the original
scoring with cut-off 6 as a gold standard. It was found that
the application of cut-off 3 completely prevented patients
from being falsely screened as positive (specificity 1.00).
However, it was also observed that about one in four pa-
tients (26 %) was wrongly classified as negative, and thus
failed to be identified as a candidate for urological referral.
In contrast, the use of cut-off 2 prevented a false negative
qualification in about two out of three patients that were
classified as such by cut-off 3, whereas a false positive test
result occurred in only 4 (2.84 %) and 3 (2.19 %) patients
of the total group. When considering accuracy as an
Table 1 Actionable scores according to the original scoring
system (0 to 24) and the simplified scoring system (0 to 8) in
MS patients at two assessments with a week interval
Patients Mean SD Minimum Maximum
Test 1 original scoring N = 141 8.0000 3.9943 0 18
Test 2 original scoring N = 137 7.6131 4.0041 0 21
Test 1 simplified scoring N = 141 2.4397 1.8220 0 8
Test 2 simplified scoring N = 137 2.2628 1.7710 0 7
Table 2 Numbers of patients tested positive and tested negative
with the simplified scoring using the cut-off points 3 and 2,
compared to the original scoring (cut-off point 6) at Test 1
Cut-off point 3 vs. original scoring Cut-off point 2 vs. original scoring
> = 6 <6 Total > = 6 <6 Total
> =3 61 0 61 > = 2 84 4 88
<3 38 42 80 <2 15 38 53
Total 99 42 141 Total 99 42 141
Table 3 Numbers of patients tested positive and tested negative
with the simplified scoring using cut-off points 3 and 2 compared
to the original scoring (cut-off point 6) at Test 2
Cut-off point 3 vs. original scoring Cut-off point 2 vs. original scoring
> = 6 <6 Total > = 6 <6 Total
> = 3 56 0 56 > = 2 82 2 84
<3 36 45 81 <2 10 43 53
Total 92 45 137 Total 92 45 137
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overall measure of test performance, it appears that the use
of cut-off point 3 achieved less than the use of cut-off 2:
about 0.73 vs. 0.89.
We hypothesized that a positive test result would be as-
sociated with urological treatment and with bladder-
specific medication. Only a positive test according to the
original scoring with cut-off 6 was indeed associated with
these two conditions, whereas the simplified scoring with
cut-off 3 was associated only with urological treatment,
and the simplified scoring with cut-off 2 only with the use
of bladder-specific medication. This suggests that the ori-
ginal scoring might result in a more valid screening, which
could relate to the more differentiated scoring system of 0
to 24.
The study data were acquired via patients’ self-report.
Given the well-known prevalence of cognitive impair-
ment in patients with MS [7], it may be thought that
cognitive impairment may have interfered with the qual-
ity of our data, and thus with the study’s conclusions.
However, Gold et al. have demonstrated that cognitive
impairment in MS patients does not affect the reliability
and validity of self-report health measures [8]. Therefore,
we are confident that the quality of our outcomes were
not affected by cognitive dysfunction.
The evaluation of a screening tool generally focuses
on specificity, as this measure has a greater impact on
predictive values [3]. In a study in women with incontin-
ence due to overactive bladder, it was demonstrated that
the use of the Actionable questionnaire with cut-off score
3 strongly distinguishes between patients who should be
treated vs. those who do not require treatment [3]. A total
score of ≥ 3 showed a sensitivity of 0.79 and a specificity of
0.98 with respect to the clinician-based assessment of
whether or not treatment was needed [3]. In MS patients,
however, the use of cut-off point 3 has not been validated
by sensitivity and specificity values relating to clinician-
based evaluations. In our study we also did not relate the
scores to the outcome of clinical assessments, but by using
the original scoring with cut-off 6 as a gold standard we
approximated the Actionable’s performance values in MS
patients. Our data suggest that in MS the use of cut-off 3
is indeed associated with a very high specificity (1.00), but
unintentionally results in a possibly unacceptably high
number of patients (26 %) that, although being screened
negative, actually might need urological referral. Remark-
ably, the use of cut-off point 2 resulted in both a high
specificity of 0.90–0.96, and a high sensitivity of 0.85–0.89.
Yet, the comparison of the performance values obtained
in our MS study with those in the urogynaecological
patients is indirect, as the comparator in the latter was a
clinician-based assessment [3]. It is our intention to
perform a prospective study on the use and the added
value of the Actionable questionnaire in real-life practice
in The Netherlands, with instrumental urological assess-
ments, such as flowmetry, post-void residual assessment
or cystometry, and a comparison of the original scoring
with the two simplified scorings.
Circumstantial evidence in favour of cut-off point 2 in
MS, is the fact that application of the ratio of means
(0.3050 at Test 1 and 0.2972 at Test 2) to the cut-off
point 6 of the original scoring would result in a cut-off
of 1.83–1.78 (Test 1, Test 2), which is indeed closer to 2
than 3.
Conclusions
If the simplified scoring (0 to 8) of the Actionable ques-
tionnaire is used, in MS patients the cut-off point 2 is likely
to be more accurate than the cut-off point 3, especially by
preventing a considerable number of patients from being
withheld referral to an urologist (false negatives). Further,
Table 4 Performance measures of the simplified scoring (0 to 8)
with cut-off points 3 and 2, using the original scoring system (0
to 24) and cut-off point 6 as a gold standard
Measures of
performance
Test 1 (N = 141) Test 2 (N = 137)
Cut-off Cut-off Cut-off Cut-off
Point 3 Point 2 Point 3 Point 2
True Positives 43.26 % 59.57 % 40.88 % 59.85 %
True Negatives 29.79 % 26.95 % 32.85 % 31.39 %
False Positives 0.00 % 2.84 % 0.00 % 1.46 %
False Negatives 26.95 % 10.63 % 26.28 % 7.30 %
Sensitivity 0.62 0.848 0.608 0.891
Specificity 1.00 0.904 1.00 0.956
Positive Predictive Value 1.00 0.954 1.00 0.976
Negative Predictive Value 0.525 0.716 0.555 0.811
Accuracy 0.730 0.865 0.737 0.912
Table 5 Percentages of MS patients treated by an urologist and percentages receiving bladder-specific drug treatment in relation to
positive and negative test results according to the original scoring and simplified scoring systems
N = 141 Original scoring cut-off 6 Simplified scoring cut-off 3 Simplified scoring cut-off 2
Positive Negative Positive Negative Positive Negative
70.21 % 29.79 % 43.26 % 56.74 % 62.41 % 37.59 %
Treated by urologist 46.46 % 23.81 %* 50.82 % 31.25 %** 44.32 % 32.08 %
Bladder medication 37.37 % 19.05 %*** 36.07 % 28.75 % 38.64 % 20.75 %****
*P = 0.0119; **P = 0.0186; ***P = 0.0328; ****P = 0.0274
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our data suggest that preferentially the Actionable item
scoring should be as described originally by Bates et al.,
from 0 to 3, which results in a total score ranging from 0
to 24 [1]. Future studies of the Actionable in MS patients
are needed to prospectively assess the sensitivity and speci-
ficity of the cut-off points 3 and 2 with respect to clinician-
based assessments of whether or not urological treatment
is needed.
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